^AMSTERDAM, Oct. 26, 2025 (GLOBE NEWSWIRE) — Polpharma Group, one of the…
largest pharmaceutical companies in Central and Eastern Europe and Central Asia
announced a planned change in leadership.
Effective January 1, 2026, Markus Sieger will be CEO of the company after ten years
withdraw from the group. In line with what was agreed upon at the start of his term of office
He will continue to oversee the strategic development of the group
Support member of the supervisory board.
Under the leadership of Markus Sieger, the Polpharma Group has a significant
Growth achieved, both financially and in terms of
Building a goal-oriented organization true to the mission: We help
People to lead a healthy life in a healthy world.” The company
has proven to be a reliable partner for healthcare systems across Europe and
Central Asia establishes and provides millions of patients with high-quality,
inexpensive medications available.
Jerzy Starak, owner of Polpharma Group, expressed his appreciation:
“On behalf of the entire Polpharma community, I would like to say Markus
Thank you very much for his outstanding commitment and his visionary ideas
say in the last ten years. His leadership strengths have played a key role in this
contributed to the company in a dynamic and challenging environment
To position ourselves in the market environment, to strengthen our values and to create a strategic one
Setting course for the future. I am pleased that Markus is a member of the
Supervisory Board will continue to be part of the team.”
At the same time, the Polpharma Group is pleased with the appointment of Sebastian Szymanek
as the new CEO effective January 1, 2026. Sebastian is
currently Chairman of the Board of Directors of Zak?ady Farmaceutyczne Polpharma SA in
Poland.
With almost 30 years of experience in the Pharmaceutical industry brings in Sebastian
in-depth understanding of both the generics and innovation industries
with. Since joining Polpharma in 2007, he has had several central positions
Hold management positions in the commercial area. In 2014 he became
He was Managing Director for Poland from 2017 to March 2021
Chairman of Polpharma Biuro Handlowe. Leading since September 2021
he Zak?ady Farmaceutyczne Polpharma SA as Chairman of the Board.
During his 18 years at Polpharma, Sebastian made a significant contribution to this
contributed to establishing the company as a dynamic market leader. Under
Among other things, he implemented strategic projects, cross-functional teams
managed and strengthened the company’s market position at home and abroad.
Nick Haggar, Chairman of Polpharma Group’s Board of Directors, noted:
“I am convinced that Sebastian has the right qualifications
to lead the Polpharma Group into the next phase. Thanks to his well-founded
Knowledge of the company, its proven leadership qualities, its
operational focus and his unwavering commitment to our mission
it meets all the requirements for further growth and innovative strength
to advance the group.”
About Polpharma Group
Polpharma Group is a leading regional pharmaceutical manufacturer. The
Group operates in Central and Eastern Europe, the Caucasus and Central Asia. Since
The company has enjoyed the trust of patients for over 90 years,
medical professionals and business partners and provides patients and
business partners around the world with modern medicines, active ingredients and
innovative solutions available. Every year in the factories
Polpharma Group manufactured 400 million packs of medicines directly or
sold through a partner network in over 40 countries worldwide. The
Polpharma Group includes the following companies: Zak?ady Farmaceutyczne Polpharma
SA in Poland, Zak?ady Farmaceutyczne Santo in Kazakhstan and Farmaprojects in
Spain, 089Farm in Germany and Swiss Pharma International in Switzerland.
The group employs 5,600 people.
For media inquiries please contact:
Beata Zdu?czyk-Gol?dzinowska
Head of Corporate Communications
[email protected] (mailto:[email protected])
Source: Polpharma Group
°